Section 1: Identification

Material: Norgestimate and Ethinyl Estradiol Tablets USP
0.25 mg and 0.035 mg

Manufacturer: Lupin Limited
Pithampur (M.P.) - 454 775
India

Distributor: Lupin Pharmaceuticals, Inc.
111 South Calvert Street,
Harborplace Tower, 21st Floor,
Baltimore, Maryland 21202
United States
Tel. 001-410-576-2000
Fax. 001-410-576-2221

Section 2: Hazard(s) Identification

Health

Do not prescribe norgestimate and ethinyl estradiol tablets to women who are known to have the following conditions:

- A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:
  - Smoke, if over age 35
  - Have deep vein thrombosis or pulmonary embolism, now or in the past
  - Have inherited or acquired hypercoagulopathies
  - Have cerebrovascular disease
  - Have coronary artery disease
  - Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)
  - Have uncontrolled hypertension
  - Have diabetes mellitus with vascular disease
  - Have headaches with focal neurological symptoms or migraine headaches with aura
    - Women over age 35 with any migraine headaches
- Liver tumors, benign or malignant, or liver disease
- Undiagnosed abnormal uterine bleeding
- Pregnancy, because there is no reason to use COCs during pregnancy
- Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past
Environment
No information is available about the potential of this product to produce adverse environmental effects.

Section 3: Composition/Information on Ingredients

Section 3, Composition/information on ingredients

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>CAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norgestimate USP</td>
<td>35189-28-7</td>
</tr>
<tr>
<td>Ethinyl Estradiol USP</td>
<td>57-63-6</td>
</tr>
</tbody>
</table>

Section 4: First-Aid Measures

Section 4, First-aid measures

Ingestion
If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

Inhalation
Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

Skin Contact
Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

Eye Contact
Flush eyes with plenty of water. Get medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment
Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient’s airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient’s vital signs, blood gases, serum electrolytes, etc.

OVERDOSAGE
There have been no reports of serious ill effects from overdosage of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.

Section 5: Fire-Fighting Measures

Section 5, Fire-fighting measures

Fire and Explosion Hazards
Assume that this product is capable of sustaining combustion.

Extinguishing Media
Water spray, carbon dioxide, dry chemical powder or appropriate foam.

Special Firefighting Procedures
For single units (packages): No special requirements needed.
For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.

**Hazardous Combustion Products**

Hazardous combustion or decomposition products are expected when the product is exposed to fire.

### Section 6: Accidental Release Measures

#### Section 6, Accidental release measures

**Personal Precautions**

Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Wear appropriate protective equipment and clothing during clean-up.

**Environmental Precautions**

Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Avoid discharge into drains, water courses or onto the ground. Inform appropriate managerial or supervisory personnel of all environmental releases.

**Clean-up Methods**

Collect and place it in a suitable, properly labeled container for recovery or disposal.

### Section 7: Handling and Storage

#### Section 7, Handling and storage

**Handling**

No special control measures required for the normal handling of this product.

Normal room ventilation is expected to be adequate for routine handling of this product.

**Storage**

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Protect from light.

### Section 8: Exposure Controls/ Personal Protection

#### Section 8, Exposure controls/personal protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.
Section 9: Physical and Chemical Properties

Physical Form
Norgestimate and ethinyl estradiol tablets USP are available in a wallet pack (NDC 68180-840-11) containing 28 tablets packed in a pouch (NDC 68180-840-11). Such three pouches are packaged in a carton (NDC 68180-840-13).

Each wallet (28 tablets) contains in the following order:
- 21 blue, round, film coated tablets, debossed with “E27” on one side and “LU” on the other side of the tablet contains 0.25 mg norgestimate and 0.035 mg ethinyl estradiol
- 7 green, round, biconvex, film coated tablets (non-hormonal placebo) debossed with ‘LU’ on one side and “E24” on the other side contains inert ingredients

Keep out of reach of children.

Section 10: Stability and Reactivity

Stable under recommended storage conditions.

Section 11: Toxicological Information

Carcinoma of Breast and Cervix
Norgestimate and ethinyl estradiol tablets are contraindicated in women who currently have or have had breast cancer because breast cancer may be hormonally sensitive.

There is substantial evidence that COCs do not increase the incidence of breast cancer. Although some past studies have suggested that COCs might increase the incidence of breast cancer, more recent studies have not confirmed such findings.

Some studies suggest that COC use has been associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.

Section 12: Ecological Information

No relevant studies identified.
Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

Section 14: Transport Information

<table>
<thead>
<tr>
<th>IATA/ICAO - Not Regulated</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>IATA Proper shipping Name</td>
<td>N/A</td>
</tr>
<tr>
<td>IATA UN/ID No</td>
<td>N/A</td>
</tr>
<tr>
<td>IATA Hazard Class</td>
<td>N/A</td>
</tr>
<tr>
<td>IATA Packaging Group</td>
<td>N/A</td>
</tr>
<tr>
<td>IATA Label</td>
<td>N/A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IMDG - Not Regulated</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>IMDG Proper shipping Name</td>
<td>N/A</td>
</tr>
<tr>
<td>IMDG UN/ID No</td>
<td>N/A</td>
</tr>
<tr>
<td>IMDG Hazard Class</td>
<td>N/A</td>
</tr>
<tr>
<td>IMDG Flash Point</td>
<td>N/A</td>
</tr>
<tr>
<td>IMDG Label</td>
<td>N/A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DOT - Not Regulated</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>DOT Proper shipping Name</td>
<td>N/A</td>
</tr>
<tr>
<td>DOT UN/ID No</td>
<td>N/A</td>
</tr>
<tr>
<td>DOT Hazard Class</td>
<td>N/A</td>
</tr>
<tr>
<td>DOT Flash Point</td>
<td>N/A</td>
</tr>
<tr>
<td>DOT Packing Group</td>
<td>N/A</td>
</tr>
<tr>
<td>DOT Label</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.